New AD drugs target the processes of Aβ and P-tau neurotoxicity, mitochondrial dysfunction, oxidative stress, metabolic disorders, and neuroinflammation [70,74,75,76,77,78]. The gene discussed is MAPT; the disease is metabolic disease.